64,560 Shares in GRAIL, Inc. $GRAL Bought by Caxton Associates LLP

Caxton Associates LLP bought a new stake in GRAIL, Inc. (NASDAQ:GRAL) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 64,560 shares of the company’s stock, valued at approximately $3,320,000. Caxton Associates LLP owned about 0.18% of GRAIL as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of GRAL. Farther Finance Advisors LLC lifted its position in GRAIL by 768.1% in the 2nd quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock valued at $42,000 after purchasing an additional 722 shares during the last quarter. Roble Belko & Company Inc bought a new stake in shares of GRAIL during the second quarter valued at approximately $68,000. Cypress Capital Management LLC WY bought a new stake in shares of GRAIL during the second quarter valued at approximately $72,000. NewEdge Advisors LLC boosted its position in shares of GRAIL by 390.3% during the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after buying an additional 1,401 shares during the period. Finally, Quarry LP grew its holdings in GRAIL by 1,965.4% in the 1st quarter. Quarry LP now owns 2,148 shares of the company’s stock worth $55,000 after buying an additional 2,044 shares in the last quarter.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Guggenheim raised GRAIL from a “neutral” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Wednesday, November 12th. Canaccord Genuity Group lifted their price objective on shares of GRAIL from $85.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Wednesday, October 8th. UBS Group set a $75.00 target price on shares of GRAIL in a research report on Friday, October 3rd. Finally, Morgan Stanley raised their target price on shares of GRAIL from $85.00 to $110.00 and gave the company an “equal weight” rating in a research note on Monday, December 1st. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, GRAIL has an average rating of “Hold” and a consensus price target of $97.50.

GRAIL Stock Down 4.5%

Shares of GRAL stock opened at $90.82 on Monday. The stock has a 50-day simple moving average of $87.52 and a 200 day simple moving average of $56.94. GRAIL, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $115.76. The stock has a market capitalization of $3.54 billion, a P/E ratio of -7.81 and a beta of 4.22.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.46) EPS for the quarter, topping the consensus estimate of ($3.40) by $0.94. GRAIL had a negative net margin of 286.43% and a negative return on equity of 15.69%. The firm had revenue of $36.19 million for the quarter, compared to analysts’ expectations of $33.83 million. On average, sell-side analysts anticipate that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Insider Activity at GRAIL

In other GRAIL news, CEO Robert P. Ragusa sold 7,239 shares of the company’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $68.88, for a total value of $498,622.32. Following the transaction, the chief executive officer owned 727,388 shares of the company’s stock, valued at approximately $50,102,485.44. This represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Joshua J. Ofman sold 6,114 shares of the firm’s stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $82.01, for a total value of $501,409.14. Following the sale, the president directly owned 381,818 shares of the company’s stock, valued at approximately $31,312,894.18. This represents a 1.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 113,295 shares of company stock valued at $7,380,888.

GRAIL Company Profile

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.